CooperCompanies stock (US21664P1039): focus shifts to contact lens and fertility growth after latest results

CooperCompanies is back in the spotlight after releasing its latest quarterly figures and updating guidance, giving investors new insight into the trajectory of its contact lens and fertility businesses. The medical device group reported higher revenue driven by demand for specialty contact lenses and fertility products, while profitability and margins remained key topics for the market, according to CooperCompanies investor information as of 03/01/2024 and coverage by Reuters as of 03/01/2024.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

CooperCompanies: core business model

CooperCompanies operates as a specialty medical device group with a focus on eye care and fertility solutions, positioning itself in segments that benefit from structural health trends. The business is organized primarily into CooperVision, which develops and sells contact lenses, and CooperSurgical, which focuses on fertility and women’s health technologies, as described in the company’s filings and earnings materials released on 03/01/2024 for the quarter ended 01/31/2024, according to CooperCompanies quarterly report as of 03/01/2024.

The CooperVision unit is centered on soft contact lenses for the correction of common vision problems, including myopia, hyperopia and astigmatism. Within this portfolio, the group emphasizes specialty products such as toric and multifocal lenses and lenses made from silicone hydrogel materials, which have gained share in the global market. The company states that it targets both daily disposable and reusable modalities, seeking to capture demand from consumers and eye care professionals transitioning to higher-value lens categories, as outlined in its annual report for the fiscal year ended 10/31/2023, which was made public on 12/15/2023, according to CooperCompanies annual report as of 12/15/2023.

The CooperSurgical unit concentrates on products and services used in fertility clinics and women’s health practices. This segment includes in vitro fertilization (IVF) consumables and equipment, genetic testing services associated with fertility treatment, and devices for obstetrics and gynecology. In the fiscal 2023 reporting, CooperSurgical expanded following acquisition activity in fertility and maternal health, and the company has emphasized integration and synergy realization as ongoing priorities, according to the same annual filing published on 12/15/2023. This mix gives the group exposure to both elective medical procedures and essential vision correction needs.

CooperCompanies generates the majority of its revenue outside the United States but remains closely tied to the US healthcare and consumer markets through its large installed base of eye care professionals and fertility clinics. Management has highlighted the recurring nature of contact lens demand and the high value of relationships with optometrists and ophthalmologists, which can support repeat purchases and stable cash flows. At the same time, fertility solutions are linked to demographic and social trends such as later family planning and sustained use of assisted reproductive technologies, which represent longer-term demand drivers.

Main revenue and product drivers for CooperCompanies

In the latest reported quarter for the period ended 01/31/2024, CooperCompanies posted higher revenue compared with the prior-year period, with growth led by the CooperVision unit, according to the earnings release dated 03/01/2024. The company reported that CooperVision delivered revenue growth supported by daily disposable and silicone hydrogel lenses across spherical, toric and multifocal categories, while CooperSurgical also grew, aided by fertility products and services, as detailed in CooperCompanies earnings release as of 03/01/2024.

Within CooperVision, daily disposable lenses have been a central growth driver, as consumers and practitioners continue to shift away from monthly modalities. The company has stressed the importance of its one-day silicone hydrogel offerings for astigmatism and presbyopia, which generally carry higher price points and can improve margins. In its fiscal 2023 report, CooperCompanies noted that revenue growth in CooperVision was led by sales of silicone hydrogel and specialty lenses over the year ended 10/31/2023, figures that were disclosed when the report was published on 12/15/2023, according to CooperCompanies annual report as of 12/15/2023.

For CooperSurgical, fertility products and services remain a core pillar. The company provides IVF consumables, including media and laboratory equipment, as well as genetic testing offerings used in assisted reproduction. In fiscal 2023, fertility revenue increased year on year over the twelve months ended 10/31/2023, reflecting continued demand from clinics and patients; these figures were set out in the same annual report released on 12/15/2023. However, CooperCompanies has also faced integration-related costs and margin pressure in the women’s health portfolio, which management has sought to address through cost controls and portfolio optimization.

The group’s revenue mix has implications for profitability. Contact lenses typically offer attractive gross margins, but the company has acknowledged cost headwinds from raw materials, manufacturing and distribution. In its first-quarter 2024 results for the period ended 01/31/2024, CooperCompanies reported adjusted earnings per share alongside revenue growth, highlighting that currency movements and inflation continued to play a role in margins, according to CooperCompanies earnings release as of 03/01/2024. The balance between investing for growth and protecting profitability has been a central discussion point for investors.

Guidance and outlook updates also act as key drivers for the stock. In connection with its first-quarter 2024 results, CooperCompanies provided an updated outlook for the fiscal year ending 10/31/2024, including expectations for revenue and adjusted earnings, as described in the 03/01/2024 release. Management pointed to ongoing growth in specialty contact lenses and fertility, while noting that macroeconomic conditions and healthcare spending patterns could influence the trajectory. Investors often focus on how closely the company’s guidance aligns with broader industry growth expectations in eye care and fertility services.

Industry trends and competitive position

CooperCompanies operates in competitive markets dominated by several global players. In contact lenses, the main competitors include large eye care companies that also focus on soft contact lenses and specialty products, while in fertility solutions the group is part of a fragmented landscape of medical device providers and laboratory service companies. The company’s strategy emphasizes innovation in specialty lenses and clinical relationships in fertility as a way to defend and expand market share, according to statements in the fiscal 2023 annual report dated 12/15/2023. These dynamics influence pricing power, marketing spending and long-term growth potential.

Broader industry trends provide both support and challenges. In eye care, rising rates of myopia and increased screen time have contributed to sustained demand for vision correction, while aging populations drive need for presbyopia solutions. At the same time, competition from alternative vision correction methods such as refractive surgery and potential economic pressures on discretionary health spending can temper growth. CooperCompanies has underscored the recurring nature of contact lens usage and the role of specialty designs in differentiating its portfolio. In fertility, increased awareness of assisted reproductive technologies and the trend toward later family planning support long-term growth, though regulatory changes and reimbursement policies can affect adoption rates and clinic investment cycles.

Regulation and quality standards are critical in both of CooperCompanies’ markets. Medical devices and reproductive technologies are subject to stringent oversight in the United States, Europe and other regions, which can lengthen product development timelines but also create barriers to entry. The company regularly reports on its compliance and product quality systems in its regulatory filings and corporate responsibility disclosures. For investors, the ability to navigate regulatory requirements while launching new products and services is an important factor in assessing execution risk and long-term resilience. CooperCompanies’ history in contact lenses and its growing presence in fertility may offer scale benefits that smaller competitors cannot easily replicate.

Why CooperCompanies matters for US investors

For US investors, CooperCompanies represents exposure to two healthcare niches with structural growth drivers: vision correction and fertility treatment. The stock is listed on the New York Stock Exchange under the ticker COO, with trading in US dollars, making it directly accessible to US-based portfolios and retirement accounts. Its business is sensitive to global trends but still significantly influenced by conditions in the US healthcare market, including insurance coverage, consumer spending and clinical practice patterns, as described in the company’s filings for the fiscal year ended 10/31/2023 published on 12/15/2023.

Because contact lenses are often paid out of pocket or through vision plans, consumer confidence in the United States can play a role in product mix and volume trends. Fertility services, which may be partially self-funded, also depend on household financial strength and access to financing. As a result, CooperCompanies can be influenced by broader US macroeconomic indicators such as employment levels and disposable income. At the same time, the recurring nature of medical and vision needs can provide a degree of resilience compared with more cyclical consumer sectors. Investors who follow US healthcare and medtech names often look at CooperCompanies alongside other mid- to large-cap device makers focusing on specialized therapeutic areas.

The company’s innovation pipeline and capital allocation strategy are also relevant for US-focused portfolios. CooperCompanies invests in manufacturing capacity, research and development and selective acquisitions, as described in its annual and quarterly filings. Decisions on how much cash flow is directed toward internal investment, debt reduction or shareholder returns can shape its financial profile over time. While the company has historically used acquisitions to expand its fertility and women’s health portfolio, integration and leverage levels remain closely watched by analysts and institutional investors. US market participants often compare CooperCompanies’ growth and margin trends with medtech peers to gauge relative performance within the sector.

What type of investor might consider CooperCompanies – and who should be cautious?

CooperCompanies may appeal to investors interested in healthcare exposure with a focus on specialized devices rather than pharmaceuticals or large hospital equipment. The combination of contact lenses and fertility solutions offers diversified revenue streams within the broader medical segment, potentially smoothing out fluctuations in individual product lines. Investors who prioritize companies with recurring revenue, such as those tied to regular lens replacement cycles, often pay attention to CooperVision’s performance trends and product mix shift toward higher-value, specialty lenses as outlined in the fiscal 2023 and first-quarter 2024 disclosures published on 12/15/2023 and 03/01/2024.

However, the stock might be less suitable for investors who are highly sensitive to regulatory, reimbursement or acquisition-integration risks. Fertility services can be influenced by changes in healthcare policy, insurance coverage and regional regulations, which could affect procedure volumes or clinic investment. In addition, CooperCompanies’ growth strategy includes ongoing investments in manufacturing capacity and selective M&A, which can increase execution risk and exposure to potential write-downs if integrations do not proceed as planned. Investors with a lower tolerance for earnings volatility or leverage-related concerns may therefore remain cautious, particularly when macroeconomic conditions are uncertain and borrowing costs are elevated.

Conclusion

CooperCompanies remains a notable name in US-listed healthcare, positioned at the intersection of contact lens demand and rising use of fertility treatments. Recent quarterly results for the period ended 01/31/2024, released on 03/01/2024, showed continued revenue growth driven by specialty lenses and fertility products, while also highlighting the need to manage margins and integration-related costs, according to CooperCompanies earnings release as of 03/01/2024. The company’s prospects are tied to demographic and lifestyle trends as well as to its execution on innovation, manufacturing and acquisitions. For investors, the balance between structural growth opportunities and operational risks will likely remain central when monitoring the stock’s performance on the New York Stock Exchange over the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.